Multiple cellular targets affected by cytotoxic chemotherapy

Multiple cellular targets affected by cytotoxic chemotherapy is a broad classification used to describe the various molecular structures—such as genomic DNA, RNA, and tubulin—that are disrupted by traditional anti-cancer agents [1]. Unlike targeted therapies that focus on a single protein, these agents exert their effects on multiple essential cellular components simultaneously to inhibit cell proliferation [2]. Common mechanisms include the covalent cross-linking of DNA strands by alkylating agents and the inhibition of metabolic pathways by antimetabolites [3]. Additionally, these drugs may target the mitotic spindle to prevent chromosome segregation or inhibit topoisomerase enzymes to induce lethal DNA strand breaks [4]. Because these targets are fundamental to all dividing cells, the drugs are effective against a wide range of malignancies but also cause significant damage to healthy, rapidly dividing tissues [5]. This damage results in the characteristic side effects of chemotherapy, such as bone marrow suppression and hair loss [6]. In clinical research, this term serves as a placeholder for regimen components that lack a singular, specific molecular target [7]. The use of these multi-target agents remains a cornerstone of oncology, often used in combination to overcome drug resistance and maximize tumor cell kill [8].

Other names

Cytotoxic chemotherapy targetsConventional chemotherapy targetsMulti-target cytotoxic agentsNon-specific systemic therapy targetsRegimen component targets

DNA alkylation, DNA intercalation, antimetabolite activity, microtubule stabilization, microtubule destabilization, and topoisomerase inhibition [2, 3, 4].